公开(公告)号：US20210228707A1

公开(公告)日：2021-07-29

申请号：US17000215

申请日：2020-08-21

Applicant: ModernaTX, Inc.

Inventor： Mihir Metkar ,  Vladimir Presnyak ,  Guillaume Stewart-Jones

IPC: A61K39/215 ,  C07H21/02 ,  A61K9/16

Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US20220323572A1

公开(公告)日：2022-10-13

申请号：US17518542

申请日：2021-11-03

Applicant: ModernaTX, Inc.

Inventor： Mihir Metkar ,  Valdimir Presnyak

IPC: A61K39/215 ,  A61K9/16 ,  C07H21/02

Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US20250017867A1

公开(公告)日：2025-01-16

申请号：US18695076

申请日：2022-09-30

Applicant: ModernaTX, Inc.

Inventor： Michael Albert Zimmer ,  Xinhua Yan ,  Mihir Metkar ,  David Reid

IPC: A61K9/51 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/22

Abstract: This disclosure relates to mRNA therapy for the treatment of relaxin-related diseases, disorders or conditions such as, e.g., fibrosis or cardiovascular disease (e.g., acute heart failure or acute coronary syndrome). mRNAs for use in the invention, when administered in vivo, encode relaxin. mRNA therapies of the disclosure increase and/or restore deficient levels of relaxin expression and/or activity in subjects.

公开(公告)号：US20230355743A1

公开(公告)日：2023-11-09

申请号：US18028126

申请日：2021-09-24

Applicant: Guillaume STEWART-JONES, ,  ,Mihir METKAR ,  Vladimir PRESNYAK, ,  ModernaTX, Inc.

Inventor： Guillaume Stewart-Jones ,  Mihir Metkar ,  Vladimir Presnyak

IPC: A61K39/215 ,  C07K14/005 ,  A61K9/127 ,  A61P31/14

CPC classification number: A61K39/215 ,  C07K14/005 ,  A61K9/127 ,  A61P31/14 ,  A61K2039/53

Abstract: The disclosure provides coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US20240384277A1

公开(公告)日：2024-11-21

申请号：US18569888

申请日：2022-06-14

Applicant: ModernaTX, Inc.

Inventor： Ruchi Jain ,  Brian Robert Fritz ,  Mihir Metkar

IPC: C12N15/63 ,  C12N9/22 ,  C12N15/88

Abstract: The disclosure features compositions or systems and uses thereof, comprising a first polynucleotide encoding a target molecule, optionally a second polynucleotide encoding an effector, repressor, or endonuclease molecule; optionally a recognition or cleavage site in the first or second polynucleotide, and optionally a repressor/effector binding site in the first polynucleotide. The compositions or systems of the present disclosure can increase the level and/or activity of the target molecule in desired cells and/or microenvironments while suppressing the level and/or activity of the target molecule in off-target cells and/or microenvironments.

公开(公告)号：US20230346914A1

公开(公告)日：2023-11-02

申请号：US17797784

申请日：2021-02-06

Applicant: ModernaTX, Inc.

Inventor： Guillaume Stewart-Jones ,  Andrea Carfi ,  Sayda Mahgoub Elbashir ,  Mihir Metkar

IPC: A61K39/215 ,  A61K39/145 ,  A61K47/10 ,  A61P37/04

CPC classification number: A61K39/215 ,  A61K39/145 ,  A61K47/10 ,  A61P37/04 ,  A61K2039/53

Abstract: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of coronavirus.